Catalent Acquires R.P. Scherer Eberbach

News   Mar 02, 2012

 
Catalent Acquires R.P. Scherer Eberbach
 
 
 

RELATED ARTICLES

Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until Now

News

A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.

READ MORE

Sekisui XenoTech Appoints New COO

News

Company hires CRO & pharma veteran, Dr. Darren Warren, as new Chief Operating Officer.

READ MORE

Researchers Reveal How Superbug Secretes It’s Toxin

News

Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE